Evommune (EVMN) Cash from Operations (2024 - 2026)
Evommune's (EVMN) quarterly Cash from Operations came in at 27503000.0 in Q1 2026, down 15.08% year-on-year from 32387001.58 in Q1 2025, and down 64.7% on a QoQ basis from 16699000.0 in Q4 2025.
Evommune (EVMN) Cash from Operations (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Cash from Operations data on file, last reported at 27503000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations fell 15.08% year-over-year to 27503000.0 in Q1 2026; TTM through Mar 2026 was 86613000.0, a N/A change from a year earlier, with the FY2025 full-year figure at 76441000.0, down 31.35% from the prior year.
- Cash from Operations for Q1 2026 stood at 27503000.0, down from 16699000.0 in the prior quarter.
- Over the last five years, Cash from Operations for EVMN reached as high as 16699000.0 in Q4 2025 and fell as low as 27503000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 21653250.0 across 3 years, with a median of 21205500.0 in 2024.
- Across the five-year window, Cash from Operations climbed 9.79% in 2025 and slipped 15.08% in 2026, its largest moves.
- Year by year, Cash from Operations stood at 18512000.0 in 2024, then climbed by 9.79% to 16699000.0 in 2025, then sank by 64.7% to 27503000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 27503000.0 in Q1 2026, 16699000.0 in Q4 2025, and 23899000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | -27.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.50 Mn |
| Mar 31, 2026 | -27.50 Mn |
| Dec 31, 2025 | -16.70 Mn |
| Dec 31, 2025 | -16.70 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Dec 31, 2024 | -18.51 Mn |
| Dec 31, 2024 | -18.51 Mn |